Voriconazole serum concentrations in obese and overweight immunocompromised patients: A retrospective review

Pharmacotherapy

Volumn 33, Issue 1, 2013, Pages 22-30

  Davies Vorbrodt, Samantha ^a   Ito, James I ^a   Tegtmeier, Bernard R ^a   Dadwal, Sanjeet S ^a   Kriengkauykiat, Jane ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Hematologic malignancy; Immunocompromised; Obese; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; VORICONAZOLE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CANCER CENTER; CONTROLLED STUDY; DEMOGRAPHY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBESITY; RETROSPECTIVE STUDY; REVIEW; STEADY STATE; SYSTEMIC MYCOSIS;

BODY MASS INDEX; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84875465024     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1156     Document Type: Review

References (37)

1. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995;20(6):1531-4.
2. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002;17(3):168-75.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32 (3):358-66.
4. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41(9):1232-9.
5. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant- Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010;50(8):1091-100.
6. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34(7):909-17.
7. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15.
8. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2-12.
9. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45(7):883-93.
10. Wingard JR, White MH, Anaissie EJ, Raffalli J, Goodman J, Arrieta AC. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empiricial treatment of febrile neutropenia. L Amph/ABLC collaborative study group. Clin Infect Dis 2000;31:1155-63.
11. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303(3):235-41.
12. Cohen LG, DiBiasio A, Lisco SJ, Hurford WE. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy 1997;17(5):1023-6.
13. Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 2008;60(3):329-31.
14. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44(6):590-8.
15. Lee DG, Chae H, Yim DS, et al. Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. J Clin Pharm Ther 2009;34(3):337-44.
16. Kriengkauykiat J, Dadwal SS, Ito J. Antifungal agents: use for empiric therapy for invasive fungal infections in patients other than a 70-kg, middle-aged male, with normal renal and liver function. CJHP 2009;21(2):6-20.
17. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO technical report series 894. Geneva: World Health Organization, 2000. Available fromhttp://whqlibdoc.who.int/trs/ WHO-TRS-894.pdf. Accessed January 25, 2012.
18. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945-56.
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15(6):825-8.
20. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813-21.
21. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008;47(5):674-83.
22. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002;10(suppl 2):97S-104.
23. Pascual AA, Bolay S, Marchetti O. Documentation of low voriconazole blood levels followed by dose adjustment in patients with invasive fungal Infections not responding to therapy [abstract M-1304]. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2006, San Francisco, California .
24. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46(2):201-11.
25. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50 (4):1570-2.
26. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45(7):649-63.
27. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109(8):1532-5.
28. Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother 2011;55(6):2601-5.
29. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(suppl 1):67-87.
30. Dodds Ashley ES, Lewis R, Lewis JS, Marin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43(suppl):S28-39.
31. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after singleor multiple-dose administration. Antimicrob Agents Chemother 2004;48(6):2166-72.
32. Lee S, Kim BH, Nam WS, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 2012;52:195-203.
33. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009;49 (2):196-204.
34. Wang G, Lei HP, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009;65 (3):281-5.
35. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34(5):563-71.
36. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46(2):235- 43.
37. Michael C, Bierbach U, Frenzel K, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother 2010;54(8):3225-32.